#1
|
|||
|
|||
Ãëþêîçà 5.9
Çäðàâñòâóéòå, ìóæ÷èíà 31ã èìåþ ëèøíèé âåñ èìò îêîëî 35 , òàêæå îòåö áîëåë äèàáåòîì, ïîýòîìó ÿ êàæäûå ïîëãîäà èëè ÷àùå ñäàþ àíàëèçû äëÿ ñêðèíèíãà. 06.08.2022 ñäàâàë ãëèêèðîâàííûé 4.8, ãëþêîçà 4.9 , à ïîñëåäíèå äâà ìåñÿöà èç çà ñòðåññà ïîäíàáðàë åù¸ îêîëî 6-7 êã, äîâîëüíî ìíîãî åë, áûë àëêîãîëü, â èòîãå ñåãîäíÿ ðåøèë ïåðåñäàòü ãëèêèðîâàííûé 4.6 , ãëþêîçà 5.9 ( íîðìà ëàáîðàòîðèè 5.83), â îáùåì òàêóþ öèôðó íàòîùàê ïîëó÷èë âïåðâûå çà îãðîìíîå ìíîæåñòâî àíàëèçîâ, âñå ïîñëåäíèå àíàëèçû ñòàáèëüíî ïîêàçûâàëè ãëþêîçó îêîëî 5. Ñêàæèòå ïîæàëóéñòà ýòî íà÷àëî ñä èëè íîðìà? Ïðî äèåòó è ñáðîñ âåñà ÿ åñòåñòâåííî ïîíèìàþ. Òàêæå âòîðîé âîïðîñ äîïóñòèì ëàòåíòíîñòü ê ãëþêîçå ðåàëüíî îáðàòèìà, íå êîìïåíñàöèè, à èìåííî îáðàòèìîñòü íîðìàëèçàöèè óãëåâîäíîãî îáìåíà
|
#2
|
||||
|
||||
äàæå óñòàíîâëåííûé äèàãíîç ñàõ. äèàáåò 2 îáðàòèì, åñëè çàíÿòüñÿ ñîáîþ, íèçêîóãëåâîäíàÿ ãèïîêàëîð. äèåòà ê âàøóì óñëóãàì
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#3
|
||||
|
||||
Òåðìèíà « ëàòåíòíîñòü ê ãëþêîçå « íåò â ïðèðîäå.
Êàæäûé ðàç, êîãäà Âàñ áóäåò òÿíóò ê ðàçìûøëèçìàì, ñäåëàéòå ïàðó êðóãîâ áûñòðûì øàãîì âîêðóã Âàøåãî äîìà. Äàâàéòå âñåðü¸ç ðàáîòàòü íàä ïèòàíèåì , à íå íàä âåðñèÿìè
__________________
Ã.À. Ìåëüíè÷åíêî |
#4
|
||||
|
||||
Duration is crucial, as shown by 60% remission (9 of 15 participants) with a duration of less than 4 years, compared with
21% (two of 14 participants) with a duration of more than 8 years assessed after 6 months of follow-up... [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] âàæíîñòü äèåòû, à íå ïîòåðè âåñà íà ðåâåðñ äèàáåòà: a weight loss VLCD study by Henry et. al. [15] of 30 obese adults (mean BMI >35) with T2D, reported that within just 10 days of the VLCD, 87% of intervention subjects (26/30) showed significant reductions (p < 0.001) in FPG, insulin levels, and hepatic glucose output (HGO), while losing only ~4% of their initial body weight ... with VLCD, short-term onset of T2D remission can occur with even negligible weight loss, and for some individuals, modest reductions in body weight of 10–15% that have been documented in numerous VLCD studies, are sufficient for maintaining T2D remission in the long-term.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#5
|
|||
|
|||
Ïîíèìàþ, ÷òî âèäèìî ñëîæíî áóäåò ïîëó÷èòü îòâåòû, íî âñå æå ñïðîøó:
5.9 ýòî íîðìà, öèôðà ðåôåðåíòíà òî åñòü çàâòðà ìîæåò áûòü íèæå ? Åñòü ëè ïîíèìàíèå çà êàêîé âðåìÿ ìîæåò ðàçâèòüñÿ ñä, íó íå ìîãó æå ÿ êàæäóþ íåäåëþ ñäàâàòü àíàëèç? ×òî òî ñåé÷àñ íàäî åù¸ ñäàòü? Çàðàíåå ñïàñèáî. Ïðîñòî ÿ ÷¸òêî ñëåæó çà ñàõàðîì è âïåðâûå âûÿâèëè 5.9, ÿ ïðîñòî ñîðâàëñÿ èç çà ñòðåññà è ïîäíàáðàë åù¸ âåñà çà ýòè äâà ìåñÿöà, ñòðåññ èç çà ïðîèñõîäÿùèõ ñîáûòèé â ìèðå..çíàþ ÷òî îïðàâäàíèå |
#6
|
||||
|
||||
ïîïðîñèòå âàñ çàïåðåòü â êàìåðå îäèíî÷êå, ÷òîá íå òûðèëè åäó ó ñîáðàòüåâ ïî êëåòêå, è ÷åðåç íåñê. ìåñ. âñå ïîêàçàòåëè áóäóò â íîðìå
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#7
|
||||
|
||||
×òî Âû ïîíèìàåòå ïîä òåðìèíîì» ðåôåðåíòíà, òî åñòü çàâòðà ìîæåò áûòü íèæå» - îòêóäà ýòîò ñòðåìëåíèå ôëóäèòü âìåñòî òîãî, ÷òîáû äåéñòâîâàòü?
Ïðè îòöå ñ Ñä2 è îæèðåíèè ó Âàñ 99 % øàíñîâ ðàçâèòèÿ ÑÄ 2 - âîïðîñ òîëüêî â òîì , áóäåò ëè ýòî çàâòðà èëè â 115 ëåò À íîðìàëèçàöèÿ ìàññû óæå ñíèçèò øàíñû
__________________
Ã.À. Ìåëüíè÷åíêî |
#8
|
|||
|
|||
Öèòàòà:
|
#9
|
||||
|
||||
Ó Âàñ îäíîêðàòíî âûÿâëåíà ãëèêåìèÿ 5.9 ììîëü/ ë
Ñ ó÷åòîì Âàøåãî îæèðåíèÿ ìîæíî ãîâîðèòü î ãèïåðãëèêåìèè íàòîùàê êàê î ïðåäèàáåòå, ñêîðåå âñåãî ìîæíî èñïîëüçîâàòü òåðìèí « ìåòàáîëè÷åñêèé ñèíäðîì». Ñàìî îæèðåíèå íèêàê íå íîðìà. ×òî â èìåíè òåáå ? ( ñ) Êîíå÷íî, íå íàäî « ñàäèòüñÿ íà äèåòó» - ïîòîìó êàê øòàíû èñïà÷êàåòå îâîùàìè. Íó à íàéòè ñòàòüþ â Èíåòå î ïîëüçå àëêîãîëèçìà èëè îæèðåíèÿ íå ñëîæíî. Îæèðåíèå áåç ëå÷åíèÿ ïðîãðåññèðóåò íåèçáåæíî
__________________
Ã.À. Ìåëüíè÷åíêî |